International Stem Cell Corporation (OTCBB:ISCOE) announced today that Kenneth Aldrich, Chairman, will present to investors as part of the Lippert/Heilshorn & Associates Life Sciences & Medical Technologies Virtual Conference on Thursday, June 16, 2011 at 10:30 a.m. Eastern.
A webcast of the presentation will be accessible online at www.internationalstemcell.com, or the PrecisionIR event site: www.vcall.com/CustomEvent/lipper/index.asp. An archived version will be available for 30 days.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation Kenneth C Aldrich, Chairman 760-940-6383 firstname.lastname@example.org or Lippert/Heilshorn & Associates Don Markley 310-691-7100 email@example.com